Alpha Teknova (TKNO) Reports Prelim Q4 Revenue of $10-$10.1M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Teknova Announces Preliminary Revenue of $10.0 to $10.1 Million for the Fourth Quarter 2021
February 28, 2022 8:15 AM ESTCompany to participate in two upcoming investor conferences in March 2022
HOLLISTER, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (Teknova) (Nasdaq: TKNO), a leading provider of critical reagents for the discovery, development, and commercialization of drug therapies, novel vaccines, and molecular diagnostics, today announced preliminary unaudited revenue for the fourth quarter ended December 31, 2021, of $10.0 to $10.1 million, including Sample Transport of approximately $0.5 million.  Excluding Sample Transport, total unaudited revenue for the fourth quarter ended December 31, 2021, was $9.5 to $9.6 million.
"Our team delivered an outstanding finish to 2021, resulting in... More
